{"id":639,"date":"2020-11-09T10:32:58","date_gmt":"2020-11-09T10:32:58","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=639"},"modified":"2020-11-09T10:32:58","modified_gmt":"2020-11-09T10:32:58","slug":"06-nov-2020-artemisinin-in-combination-with-piperaquine-significantly-reduced-the-time-to-reach-undetectable-sars-cov-2","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/06-nov-2020-artemisinin-in-combination-with-piperaquine-significantly-reduced-the-time-to-reach-undetectable-sars-cov-2\/","title":{"rendered":"(06 Nov 2020) Artemisinin- in combination with Piperaquine significantly reduced the time to reach undetectable SARS-CoV-2"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial<\/p>\n<p>https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106216<\/p>\n<p class=\"\">In an open label clinical trial (ChiCTR2000033049), Forty-one patients with confirmed COVID-19 were enrolled in the study and divided into two groups: artemisinin-piperaquine (AP) group (n=23) and control group (n=18). The primary outcome was the time taken to reach undetectable levels of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) and the percentage of participants with undetectable SARS-CoV-2 on day 7, 10, 14, and 28. The mean time to reach undetectable viral RNA (mean+\/- standard deviation) was 10.6+\/-1.1 days (95% confidence interval [CI]: 8.4-12.8) for AP group and 19.3+\/-2.1 days (95% CI: 15.1-23.5) for the control group. The percentage of patients with undetectable viral RNA on day 7, 10, 14, 21, and 28 were 26.1%, 43.5%, 78.3%, 100%, and 100%, respectively, in the AP group and 5.6%, 16.7%, 44.4%, 55.6% and 72.2%, respectively, in the control group. The CT imaging within ten days post-treatment showed no significant differences between the two groups (p&gt;0.05). Both groups had mild adverse events.&nbsp; In patients with mild to moderate COVID-19, the time to reach undetectable SARS-CoV-2 was significantly shorter in the AP group than that in the control group.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106216 In an open label clinical trial (ChiCTR2000033049), Forty-one patients with confirmed COVID-19 were enrolled in the study and divided into two groups: artemisinin-piperaquine (AP)&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/06-nov-2020-artemisinin-in-combination-with-piperaquine-significantly-reduced-the-time-to-reach-undetectable-sars-cov-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(06 Nov 2020) Artemisinin- in combination with Piperaquine significantly reduced the time to reach undetectable SARS-CoV-2&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[87,6,4],"tags":[88],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/639"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=639"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/639\/revisions"}],"predecessor-version":[{"id":640,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/639\/revisions\/640"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}